ifosfamide
Not Tagged
['reecur', 'sarcoma']
high-dose ifosfamide has shown superior survival benefit over 3 other chemotherapy regimens for patients with recurring or refractory primary ewing sarcoma in the practice-changing reecur trial at #asco22. 
The leading online provider of #CME, #CNE, #CE, and #CPE across 30+ medical specialties to support health professionals in improving patient care.